Evidence map›Paper›PMID 33471276›Full record

ArticleScience China. Life sciences2021

Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19.

Qiuyu Li, Cheng Cui, Fei Xu, Jianping Zhao, Nan Li, Haichao Li, Tianbing Wang, Hua Zhang, Na Liu, Yudong Wei and 11 more

Open access · bronzeAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Science China. Life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 1 country.

Qiuyu Li *Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China.
Cheng Cui *Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
Fei Xu *Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Jianping ZhaoDepartment of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Nan LiResearch Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, China.
Haichao LiDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China.
Tianbing WangTrauma Center, Peking University People's Hospital, Beijing, 100044, China.
Hua ZhangResearch Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, China.
Na LiuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
Yudong WeiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
Xiaoye NiuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
Yan XuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
Jianping DongBeijing Haidian Hospital, Haidian Section of Peking University Third Hospital, Beijing, 100080, China.
Xueting YaoDrug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
Xiaohong WangDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China.
Yahong ChenDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China.
Haiyan LiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
Chunli SongInstitute of Medical Innovation, Peking University Third Hospital, Beijing, 100191, China.
Jie QiaoInstitute of Medical Innovation, Peking University Third Hospital, Beijing, 100191, China.
Dongyang LiuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com.
Ning ShenDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China. shenning1972@126.com.
Peking University · CNPeking University Third Hospital · CNBeijing Haidian Hospital · CNFirst Affiliated Hospital of Nanchang University · CNHuazhong University of Science and Technology · CNPeking University People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentPneumoniaAntiviral AgentsChloroquineHumansHydroxychloroquineSARS-CoV-2Antiviral AgentsChloroquineHydroxychloroquine

Identifiers

PMID33471276
PMCPMC7816738
OpenAlexW3121205241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.